{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.5","upperLimit":"30.6","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1158"}],"units":"Participants"}],"description":"Match rate will be calculated as the percent of eligible patients who have an actionable mutation of interest and are matched to at least one of the subprotocols, and confidence intervals will be constructed using the Wilson score interval method. Patients enrolled on or after Amendment 4 will not be included in this analysis as screening of unselected patients will no longer be conducted.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo biopsy along with tumor mutational screening of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Patients also undergo collection of blood samples for research purposes.","id":"OG000","title":"NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol"}],"paramType":"NUMBER","populationDescription":"Patients enrolled after Amendment 4 are not included in this analysis","reportingStatus":"POSTED","timeFrame":"Up to 2 years from study entry","title":"Proportion of Pediatric Patients Whose Advanced Tumors Have Pathway Alterations That Can be Targeted by Select Anti-cancer Drugs","type":"PRIMARY","unitOfMeasure":"Percentage of patients"}